NEW YORK (GenomeWeb News) – Diaxonhit today announced an agreement with Boehringer Ingelheim to discover and characterize novel splice variants that potentially could be therapeutic targets for oncology.

Paris-based Diaxonhit will use its SpliceArray discovery platform to identify potential targets and then build a database of specific splice variants. Boehringer Ingelheim has the option to buy the rights to research, develop, and commercialize any targets discovered by Diaxonhit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Uncovering variants associated with diabetes-related kidney disease, a sequencing study of hepatitis E viruses circulating in Cambodia, and more.

Among Sacks' books was "Awakenings," which was later made into an Academy Award-winning film.

The popularity of the #sciencemoviequote Twitter trend showcases scientists' eclectic movie tastes and knack for puns. 

The popular astrophysicist warned that apathy and even contempt for science in politics could lead to the end of informed democracy.